Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Biostar Completes Recruitment for US Phase 1 Study of Utidelone Capsule
Details : UTD2 (utidelone) is the only approved innovative microtubule inhibitor developed using synthetic biology technology. It is being evaluated for the treatment of advanced solid tumors.
Brand Name : UTD1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 03, 2024
Lead Product(s) : Utidelone,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Biostar Pharma Gets FDA Clearance for Phase 2 Study of Utidelone in HER2- Breast Cancer
Details : UTD1 (utidelone) is an investigational tubulin inhibitor, given intravenously in combination with capecitabine for its potential efficacy in patients with HER2-negative breast cancer brain metastases.
Brand Name : UTD1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 05, 2024
Lead Product(s) : Utidelone,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Utidelone,Bevacizumab,Etoposide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Orphan Drug Designation to Utidelone for Breast Cancer Brain Metastasis
Details : UTD1 (utidelone) is the only approved innovative microtubule inhibitor developed using synthetic biology technology. It is being evaluated for the treatment of breast cancer brain metastasis.
Brand Name : UTD1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 29, 2024
Lead Product(s) : Utidelone,Bevacizumab,Etoposide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Orphan Drug Designation to Biostar Pharma's Utidelone for Gastric Cancer
Details : UTD2 (utidelone) is the only approved innovative microtubule inhibitor developed using synthetic biology technology. It is being evaluated for the treatment of gastric cancer.
Brand Name : UTD2
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 21, 2024
Details : UTD2 (utidelone capsule) is the first oral epothilone microtubule inhibitor, which is investigated for the treatment of advanced solid tumor patients in the US.
Brand Name : UTD1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 15, 2023
Details : UTD2 (utidelone capsule) is the first oral epothilone microtubule inhibitor and which is investigated for the treatment of advanced solid tumor patients in the US.
Brand Name : UTD2
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 12, 2023
LOOKING FOR A SUPPLIER?